Hank Safferstein
senior vice president
Cognition Therapeutics, Inc.

Hank is senior vice president of Cognition Therapeutics (a clinical-stage, small molecule, Alzheimer’s disease company), executive in residence at the Pittsburgh Life Sciences Greenhouse, board director of Ariel Precision Medicine, and adjunct professor at Carnegie Mellon University.

He was founder and chief executive officer of Complexa, Inc., a clinical-stage biotechnology company focused on fibrosis and inflammation for orphan disease indications. Hank served as vice president, business development, for Omrix Biopharmaceuticals, a commercial-stage company that develops and markets biosurgical and passive immunotherapy products (acquired by J&J) and was vice president, business development, for Acorda Therapeutics, a central nervous system drug development and marketing company.

Prior to joining Acorda Therapeutics, Hank served in various business development and marketing positions with Bristol-Myers Squibb. From 1991-1997, he was director, technology transfer, at the National Heart, Lung and Blood Institute and cooperative venture manager for the National Institute of Allergy and Infectious Diseases, National Institutes of Health. Hank was an NIH postdoctoral fellow and fellow of the Multiple Sclerosis Society.

Hank received a B.A. in biochemistry from Rutgers University, a Ph.D. in human anatomy and neurobiology from the University of Louisville, a J.D. from the American University, Washington College of Law, and an M.B.A. from Columbia University. 

Learn more about Hank: https://www.linkedin.com/in/hank-safferstein-19a8767/